α-Synuclein, Parkinson's disease, and Alzheimer's disease

Parkinsonism and Related Disorders

Volumn 10, Issue SUPPL. 1, 2004, Pages S9-

  Kim, Seonghan ^a   Seo, Ji Heui ^a   Suh, Yoo Hun ^a  

^a Seoul National University   (South Korea)

Author keywords

Alzheimer's disease; Neurodegeneration; Neuroprotection; Parkinson's disease; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; BRAIN PROTEIN;

ALZHEIMER DISEASE; CELLULAR DISTRIBUTION; CONFERENCE PAPER; DEGENERATIVE DISEASE; HUMAN; IMMUNE SYSTEM; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 1942518751     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2003.11.005     Document Type: Conference Paper

References (75)

1. Chen X., Rohan de Silva H.A., Pettenati M.J., Rao P.N., St George-Hyslop P., Roses A.D., Xia Y., Horsburgh K., Uéda K., Saitoh T. The human NACP/α-synuclein gene: chromosome assignment to 4q21.3-q22 and taqI RFLP analysis. Genomics. 26:1995;425-427.
2. Spillantini M.G., Divane A., Goedert M. Assignment of human α-synuclein (SNCA) and β-synuclein (SNCB) genes to chromosome 4q21 and 5q35. Genomics. 27:1995;379-381.
3. Ueda K., Fukushima H., Masliah E., Xia X., Iwai A., Yoshimoto M., Otero D.A.C., Kondo J., Ihara Y., Saitoh T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA. 90:1993;11282-11286.
4. Jakes R., Spillantini M.G., Goedert M. Identification of two distinct synucleins from human brain. FEBS Lett. 345:1994;27-32.
5. Irizary M.C., Kim T.W., McNamara M., Tanzi R.E., George J.M., Clayton D.F., Hyman B.T. Characterization of the precursor protein of the non-Aβ component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol. 55:1996;889-895.
6. Goedert M. Filamentous nerve cell inclusions in neurodegenerative disease: tauopathies and alpha-synucleinopathies. Philos Trans R Soc Lond B Biol Sci. 354:1999;1101-1118.
7. Lavedan C. The synuclein family. Genome Res. 8:1998;871-880.
8. Goedert M., Spillantini M.G. Lewy body diseases and multiple system atrophy as alpha-synucleinopathies. Mol Psychiatry. 3:1998;462-465.
9. Goedert M., Spillantini M.G., Davies S.W. Filamentous nerve cell inclusions in neurodegenerative diseases. Curr Opin Neurobiol. 8:1998;619-632.
10. Goedert M., Jakes R., Crowther R.A., Hasegawa M., Smith M.J., Spillantini M.G. Intraneural filamentous tau protein and α-synuclein deposits in neurodegenerative disease. Biochem Soc Trans. 26:1998;463-471.
11. Golbe L.I. α-Synuclein and Parkinson's disease. Mov Disord. 14:1999;6-9.
12. Spillantini M.G., Goedert M. The α-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann NY Acad Sci. 920:2000;16-27.
13. Philipp J.K., Christian H., Hans A.K., Manuela N. Structure/function of α-synuclein in health and disease: rational development of animal models for Parkinson's and related diseases. J Neurochem. 82:2002;449-457.
14. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci USA. 97:2000;571-576.
15. Ko L., Metha N.D., Farrer M., Easson C., Hussey J., Yen S., Hardy J., Yen S.C. Sensitization of neuronal cells to oxidative stress with mutated human α-synuclein. J Neurochem. 75:2000;2546-2554.
16. Imai Y., Soda M., Inoue H., Hattori N., Mizuno Y., Takahashi R. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin. Cell. 105:(7):2001;891-902.
17. Janicki S.M., Monteiro M.J. Presenilin over expression arrests cells in the G1 phase of the cell cycle. Arrest potentiated by the Alzheimer's disease PS2(N141I) mutant. Am J Pathol. 155:(1):1999;135-144.
18. Morishima Y., Gotoh Y., Zieg J., Barrett T., Takano H., Flavell R. Beta-amyloid induces neuronal apoptosis via a mechanism that involves the c-Jun N-terminal kinase pathway and the induction of Fas ligand. J Neurosci. 21:(19):2001;7551-7560.
19. Saha A.R., Ninkina N.N., Hanger D.P., Anderton B.H., Davies A.M., Buchman V.L. Induction of neuronal death by alpha-synuclein. Eur J Neurosci. 12:(8):2000;3073-3077.
20. Shimura H., Schlossmacher M.G., Hattori N., Frosch M.P., Trockenbacher A., Schneider R. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 293:(5528):2001;263- 269.
21. Wu Q., Combs C., Cannady S.B., Gelmacher D.S., Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging. 21:(6):2000;797-806.
22. Hajimohamadreza I., Treherne J.M. The role of apoptosis in neurodegenerative diseases. Prog Drug Res. 48:1997;55-98.
23. Mochizuki H., Hayakawa H., Migita M., Shibata M., Tanaka R., Suzuki A. An AAV-derived Apaf-I dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA. 98:(19):2001;10918-10923.
24. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 17:1967;427-442.
25. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N Engl J Med. 339:1998;1044-1053.
26. Jenner P., Olanow C.W. Understanding cell death in Parkinson's disease. Ann Neurol. 44:1998;S72-S84.
27. Calne D.B. Parkinson's disease is not one disease. Parkinsonism Relat Disord. 7:2001;3-7.
28. Galvin J.E., Lee V.M., Trojanowski J.Q. Synucleinopathies: clinical and pathological implications. Arch Neurol. 58:2001;186-190.
29. Masliah E., Rockenstein E., Veinbergs I., Sagara Y., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science. 287:2000;1265-1269.
30. Van der Puttem H., Wiederhold K.H., Probst A., Barbieri S., Misti C., Danner S., Kauffmann S., Hofele K., Spooren W.P.J.M., Ruegg M.A. Neuropathology in mice expressing human α-synuclein. J Neurosci. 20:2000;6021-6029.
31. Hashimoto M., Yoshimoto M., Sisk A., Hsu L.J., Sundsmo M., Kittel A. NACP, a synaptic protein involved in Alzheimer's disease, is differentially regulated during megakaryocyte differentiation. Biochem Biophys Res Commun. 237:1997;611-616.
32. Abeliovich A., Schmitz Y., Farinas I., Choi-Lundberg D., Ho W.H., Catillo P.E. Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system. Neuron. 25:2000;239-252.
33. Li Y.J., Heming J.P., Dahlstrom A. Differential localization of alpha-, beta- and gamma-synucleins in the rat CNS. Neuroscience. 113:2002;463-478.
34. Tamo W., Imaizumi T., Tanji K., Yoshida H., Mori F., Yoshimoto M. Expression of alpha-synuclein, the precursor of non-amyloid beta component of Alzheimer's disease amyloid, in human cerebral blood vessels. Neurosci Lett. 326:2002;5-8.
35. Suh Y.H., Checler F. Amyloid precursor protein, presenilins, and α-synuclein: molecular pathogenesis and pharmacological applications in Alzheimer's disease. Pharmacol Rev. 54:(3):2002;469-525.
36. Maroteaux L., Campanelli J.T., Scheller R.H. Synuclein: a neuron-specific protein-localized to the nucleus and presynaptic nerve terminal. J Neurosci. 8:1988;2804-2815.
37. Hong L., Ko H.W., Gwag B.J., Joe E., Lee S., Kim Y.T., Suh Y.H. The cDNA cloning and ontogeny of mouse α-synuclein. Neuroreport. 9:1998;1239-1243.
38. George J.M., Jin H., Woods W.S., Clayton D.F. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron. 15:1995;361-372.
39. Kholodilov N.G., Neystat M., Oo T.F., Lo S.E., Larsen K.E., Sulzer D., Burke R.E. Increased expression of rat synuclein in the substantia nigra pars compacta identified by mRNA differential display in a model of developmental target injury. J Neurochem. 73:1999;2586-2599.
40. Stefani L., Kholodilov N., Rideout H.J., Burke R.E., Greene L.A. Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells. J Neurochem. 20:2001;6021-6029.
41. Mizuno Y., Yoshino H., Ikebe S., Hattori N., Kobayashi T., Shimoda-Matsubayashi S., Matsumine H., Kondo T. Mitochondrial dysfunction in Parkinson's disease. Ann Neurol. 44:1998;S99-S109.
42. Hsu L.J., Sagara Y., Arroyo A., Rockenstein E., Sisk A., Mallory M., Wong J., Takenouchi T., Hashimoto M., Masliah E. α-Synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 157:2000;401-410.
43. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.V.L.D., Dawson T.M., Ross C.A. Inducible expression of mutant α-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet. 10:2001;919-926.
44. Kakimura J., Kitamura Y., Takata K., Kohno Y., Nomura Y., Tanighuchi T. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the anti-parkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol. 417:2001;59-67.
45. Souza J.M., Giasson B.I., Lee V.M., Ischiropoulos H. Chaperone-like activity of synucleins. FEBS Lett. 474:2000;116-119.
46. Ostrerova N., Petrucelli L., Farrer M., Mehta N., Choi P., Hardy J., Wolozin B. α-Synuclein shares physical and functional homology with 14-3-3-proteins. J Neurosci. 19:1999;5782-5791.
47. Borghi R., Marchese R., Negro A., Marinelli L., Forloni G., Zaccheo D., Abbruzzese G., Tabaton M. Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci Lett. 287:2000;65-67.
48. Takeda A., Hashimoto M., Mallory M., Sundsumo M., Hansen L., Sisk A., Masliah E. Abnormal distribution of the non-Aβ component of Alzheimer's disease amyloid precursor/α-synuclein in Lewy body disease as revealed by proteinase K and formic acid pre-treatment. Lab Invest. 78:1998;1169-1177.
49. Takeda A., Mallory M., Sundsmo M., Honer W., Hansen L., Masliah E. Abnormal accumulation of NACP/α-synuclein in neurodegenerative disorders. Am J Pathol. 152:1998;367-372.
50. Yang F., Ueda K., Chen P., Ashe K.H., Cole G.M. Plaque-associated α-synuclein (NACP) pathology in aged transgenic mice expressing amyloid precursor protein. Brain Res. 853:2000;381-383.
51. Hashimoto M., Hsu L.J., Xia Y., Takeda A., Sisk A., Sundsmo M., Masliah E. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. Neuroreport. 10:1999;717-721.
52. Souza J.M., Giasson B.L., Chen Q., Lee V.M.Y., Ischiropoulos H. Dityrosine cross-linking promotes formation of stable α-synuclein polymers. J Biol Chem. 275:2000;18344-18349.
53. El-Agnaf O.M.A., Jakes R., Curran M.D., Middleton D., Ingenito R., Bianchi E., Pessi A., Neille D., Wallace A. Aggregates from mutant and wild-type α-synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β-sheet and amyloid-like filaments. FEBS Lett. 440:1998;71-75.
54. Kanda S., Bishop J.F., Englitis M.A., Yang Y., Mouradian M.M. Enhanced vulnerablish to oxidative stress by α-synuclein mutations and C-terminal truncation. Neuroscience. 97:2000;279-284.
55. Seo J.H., Rah J.C., Choi S.H., Shin J.K., Min K., Kim H.S., Park C.H., Kim S.H., Kim E., Lee S.H., Lee S., Suh S.W., Suh Y.H. α-Synuclein regulates neuronal survival via Bcl-2 family expression and PI3/Akt kinase pathway. FASEB J. 16:2002;1826-1828.
56. Crowder R.J., Freeman R.S. Phosphatidylinositol 3-kinase and Akt protein kinase are necessary and sufficient for the survival of nerve growth factor-dependent sympathetic neurons. J Neurosci. 18:1998;2933-2943.
57. Dudek H., Datta S.R., Franke T.F., Birnbaum M.J., Yao R., Cooper G.M., Segal R.A., Kaplan D.R., Greenberg M.E. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:1997;661-665.
58. Philpott K.L., McCarthy M.J., Klippel A., Rubin L.L. Activated phophatidylinositol3-kinase and Akt kinase promote survival of superior cervical neurons. J Cell Biol. 139:1997;809-815.
59. Matsuzaki H., Tanatani M., Mitsuda N., Namikawa K., Kiyama H., Miyake S., Tohyama M. Activation of Akt kinase inhibits apoptosis and changes in Bcl-2 and Bax expression induced by nitric oxide in primary hippocampal neurons. J Neurochem. 73:1999;2037-2046.
60. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J Biol Chem. 275:2000;10761- 10766.
61. Tsujimoto Y., Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett. 466:2000;6-10.
62. Antonsson B., Martinou J.C. The Bcl-2 protein family. Exp Cell Res. 256:2000;50-57.
63. Tsujimoto Y., Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 7:2000;1174-1181.
64. Antonsson B., Montessuit S., Lauper S., Eskes R., Martinou J.C. Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome release from mitochondria. Biochem J. 345:2000;271-278.
65. Giasson B.I., Duda J.E., Murray IV, Chen Q. IV, Souza J.M., Hurtig H.I., Ischiropoulos H., Trojanowski J.Q., Lee V.M. Oxidative damage linked to neurodegeneration by selective α-syncuclein nitration in synucleinopathy lesions. Science. 290:2000;985-989.
66. Czlonkowska A., Kurkowska-Jastrzebska I., Czlonkowski A., Peter D., Stefano G.B. Immune processes in the pathogenesis of Parkinson's disease - a potential role for microglia and nitric oxide. Med Sci Monit. 8:2002;165-177.
67. Hisanaga K., Asagi M., Itoyama Y., Iwasaki Y. Increase in peripheral CD4 bright+CD8 dull+T cells in Parkinson's disease. Arch Neurol. 58:2001;1580-1583.
68. Bas J. Lymphocyte population in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol. 113:2001;146-152.
69. Mogi M. Interleukin(IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile Parkinsonism and Parkinson's disease. Neurosci Lett. 211:1996;13-16.
70. Nagatsu Y., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J Neural Transm Suppl. 58:2000;143-151.
71. Hasegawa Y., Inagaki T., Sawada M., Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocyte/macrophages in Parkinson's disease. Acta Neurol Scand. 101:2000;159-164.
72. Brookes A.J., St Clair D. Synculein proteins and Alzheimer's disease. Trends Neurosci. 17:(10):1994;404-405.
73. Iwai A., Masliah E., Yoshimoto M., Ge N., Flanagan L., de Silva H.A. The precursor protein of non-A beta component of Alzheimer disease amyloid is a presynaptic protein of the central nervous system. Neuron. 14:(2):1995;467-475.
74. Masliah E., Iwai A., Mallory M., Ueda K., Saitoh T. Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease. Am J Pathol. 148:(1):1996;201-210.
75. Culvenor J.G., McLean C.A., Cutt S., Campbell C.V., Maher F., Jakala P., Hartmann T., Beyreuther K., Masters C.L., Li Q.X. Non-Aβ component of Alzheimer's disease amyloid (NAC) revisited. NAC and α-synuclein are not associated with Aβ amyloid. Am J Pathol. 155:1999;1173-1181.